Stock of the Day

November 10, 2026

AbbVie (ABBV)

$293.22
-$0.08 (-0.0%)
Market Cap: $516.65B

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Bull Case

Here are some ways that investors could benefit from investing in AbbVie Inc.:

  • AbbVie Inc. recently reported third-quarter earnings that exceeded expectations, with revenue of $17.40 billion and an EPS of $3.82, beating the consensus estimate of $3.73. This performance, combined with a raised full-year adjusted earnings outlook, strengthens the growth case for the stock and demonstrates the company's ability to sustain revenue growth of 10.3% year-over-year.
  • The company recently increased its quarterly dividend to $1.82, representing an annualized yield of approximately 2.5% based on recent pricing. This move signals management's confidence in cash flow generation and provides a steady income stream for investors, which is particularly attractive given the stock's defensive characteristics in the healthcare sector.
  • Wall Street analysts have shown increasing optimism, with Wells Fargo raising its price target to $340.00 and Piper Sandler to $303.00 in recent months. The consensus rating remains a "Moderate Buy," and the average price target of $297.46 suggests that the current stock price of $292.87 still offers modest upside potential relative to analyst expectations.
  • AbbVie Inc. is expanding its pipeline and research capabilities, including a global licensing deal with Nxera Pharma for an EP4 receptor agonist targeting inflammatory bowel disease and the establishment of a new research facility in Oxford, UK. These moves indicate a strategic focus on diversifying growth beyond its legacy products and investing in future therapeutic areas such as immunology and neuroscience.
  • Institutional investor interest remains strong, with 70.23% of the stock owned by institutional investors and hedge funds. Recent filings show that funds like Allspring Global Investments Holdings LLC and Cullinan Associates Inc. increased their positions in the third quarter, suggesting that large capital allocators continue to view AbbVie Inc. as a core holding in their portfolios.

AbbVie Bear Case

Investors should be bearish about investing in AbbVie Inc. for these reasons:

  • The stock is trading near its 52-week high of $302.93, with the current price at $292.87. This proximity to recent peaks leaves limited room for further short-term appreciation and increases the risk of a pullback if the market sentiment shifts or if the company fails to meet the high expectations set by its recent earnings beat.
  • AbbVie Inc. has a high dividend payout ratio of 119.10%, meaning the company is paying out more in dividends than it is earning in net income. While this provides a high yield, it may limit the company's ability to reinvest in research and development or absorb financial shocks, raising concerns about the sustainability of the dividend over the long term.
  • Insider selling activity has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026 and other executives like Perry C. Siatis and David Ryan Purdue also reducing their holdings in early 2026. Such sales can be interpreted as a lack of confidence from company insiders in the stock's near-term performance or a desire to diversify personal wealth.
  • The company faces ongoing challenges related to the decline of its legacy product, Humira, which requires continuous demonstration that newer products like Skyrizi and Rinvoq can sustain growth. Investors must remain vigilant about the durability of these newer growth drivers, as any stumble in their adoption or performance could negatively impact the company's overall trajectory.
  • Short interest in AbbVie Inc. remains significant, with approximately 15.58 million shares shorted as of the latest record date. Although short interest has decreased slightly month-over-month, the level of shorting indicates that a portion of the market remains skeptical about the stock's valuation or future performance, which could lead to volatility if these shorts are covered or if negative news emerges.

MarketBeat Week in Review – 11/2 - 11/6

Written By MarketBeat Staff on 11/7/2026

A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.

It's a rally. It's a sell-off. At the end of the week, the only thing that was clear was confusion. Investors were hoping to get clarity with the U.S. midterm elections behind them. Instead, they got more volatility.

The reason is uncertainty about future regulation surrounding data centers. The conventional wisdom suggests it may not be as bad as the worst-case scenario. But any regulation is likely to slow down a trade that looked like a runaway train.

That's likely to mean the flight to safety will continue. A strong jobs report on Friday raised the odds for the Federal Reserve to raise interest rates in December. Dividend payers may still appeal to investors seeking income, particularly those that offer a yield above the current rate of inflation.

Speaking of inflation, next week investors will get the latest reading on inflation at the consumer and producer levels. A hot number from either report will likely cement expectations for higher rates and will likely keep volatility front and center.

Articles by Thomas Hughes

AbbVie (NYSE: ABBV) hit a fresh high after an earnings beat and a dividend increase. But Thomas Hughes said the Humira era is fading, and he explained why its new growth engines face another test.

Oracle (NYSE: ORCL) may be nearing the peak of its AI spending cycle. Hughes explained what that could mean for a stock recovery.

Tempus AI (NASDAQ: TEM) surged on a beat-and-raise quarter, but analysts reacted with caution. Hughes explained what needs to happen for the rally to last.

Articles by Sam Quirke

Apple (NASDAQ: AAPL) beat estimates, but the stock sold off amid concerns about memory and AI spending. Sam Quirke pointed out the catch for investors heading into the holiday quarter.

Qualcomm (NASDAQ: QCOM) beat earnings, but soft guidance sent shares lower. Quirke explained why its fastest-growing businesses come with a catch.

Amazon (NASDAQ: AMZN) has already erased its post-earnings sell-off despite concerns over the impact of capital expenditures (CapEx) on free cash flow. Quirke asked whether the biggest opportunity is still ahead.

Articles by Chris Markoch

Marriott (NASDAQ: MAR) topped earnings estimates as fee growth outpaced room revenue. Chris Markoch explained why the stock is more than a bet on travel demand.

Two oil majors just reported, and the message was straightforward. Blue-chip stocks still work. Markoch pointed out why their results remind investors to keep it simple.

Palantir (NASDAQ: PLTR) delivered a $2.3 billion quarter, but the stock dipped after earnings. Markoch analyzed how the results put its premium valuation to the test.

Articles by Ryan Hasson

Starbucks (NASDAQ: SBUX) says its turnaround is done, and the numbers back it up. But Ryan Hasson explained the one catch investors shouldn’t overlook.

Big Tech is spending billions on AI, and someone is cashing those checks. Hasson highlighted five stocks that are getting paid.

Search growth is slowing at Alphabet (NASDAQ: GOOGL), raising questions about how it will monetize AI. Hasson asked whether those fears are warranted.

Articles by Leo Miller

Marvell Technology (NASDAQ: MRVL) fell 13% on a report that it may acquire Lumentum (NASDAQ: LITE). Leo Miller explained why markets are weighing the price tag of an optical swing for the fences.

CEOs at three underperforming companies just made notable trades in their own stock. Miller explained what those insider moves could signal.

Meta Platforms (NASDAQ: META) is planning a $100 billion push to fund its AI buildout. Miller showed why that plan has a catch for existing shareholders.

Articles by Nathan Reiff

Investors looking to play the weight-loss drug boom have more than one ETF option. Nathan Reiff compared a GLP-1-focused fund with one offering broader peptide exposure.

Waste services aren’t usually thought of as growth plays. Reiff highlighted three stocks with more growth than you might expect.

JFrog (NASDAQ: FROG) is pulling ahead of its software rivals in the AI race. Reiff explained why it could be the infrastructure company to beat.

Articles by Dan Schmidt

One waste giant has the momentum, while the other offers a safer dividend. Dan Schmidt explained which advantage matters more for investors.

Uranium prices are near historic highs, but Cameco (NYSE: CCJ) missed earnings. Schmidt explained why the stock hasn’t followed the commodity higher.

Investors are rotating away from AI after the election. Schmidt highlighted three dividend ETFs that offer different ways to navigate the sell-off.

Articles by Jeffrey Neal Johnson

Energy Transfer (TXSE: ET) missed earnings estimates. But Jeffrey Neal Johnson pointed out why the miss may be hiding its strongest advantage.

TeraWulf (NASDAQ: WULF) just landed a $19 billion deal backed by Google. Johnson provided a breakdown of why that credit backstop may be its biggest advantage.

Freeport-McMoRan (NYSE: FCX) is betting $4.5 billion on a major copper expansion. Johnson explained what the project means for its long-term growth.

Recent News